0000000001009061

AUTHOR

Alessandra Merlini

0000-0002-5280-1411

showing 2 related works from this author

Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors

2021

To investigate the correlation between CT imaging features and risk stratification of gastrointestinal stromal tumors (GISTs), prediction of mutation status, and prognosis. This retrospective dual-institution study included patients with pathologically proven GISTs meeting the following criteria: (i) preoperative contrast-enhanced CT performed between 2008 and 2019; (ii) no treatments before imaging; (iii) available pathological analysis. Tumor risk stratification was determined according to the National Institutes of Health (NIH) 2008 criteria. Two readers evaluated the CT features, including enhancement patterns and tumor characteristics in a blinded fashion. The differences in distributi…

Malemedicine.medical_specialtyMultivariate analysisGastrointestinal Stromal TumorsPopulationX-ray computedRisk Assessment030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingProgression-free survivaleducationPathologicalTomographySurvival analysisGastrointestinal stromal tumors; Mutation; Progression-free survival; Survival analysis; Tomography X-ray computed; Aged; Female; Humans; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Risk Assessment; Tomography X-Ray Computed; Gastrointestinal Stromal TumorsNeuroradiologyAgedRetrospective Studieseducation.field_of_studybusiness.industryProportional hazards modelTomography X-ray computedHazard ratioProgression-free survivalGeneral MedicineSurvival analysisMiddle AgedPrognosis030220 oncology & carcinogenesisMutationFemaleRadiologyGastrointestinal stromal tumors Mutation Progression-free survival Survival analysis Tomography X-ray computedbusiness
researchProduct

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

2021

Background Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods Institutional registries a…

Phenylurea CompoundOncologyCancer Researchmedicine.medical_specialtyScheduleStromal cellPyridinesGastrointestinal Stromal TumorsPyridinePersonalized treatmentchemical and pharmacologic phenomenaMultikinase inhibitorchemistry.chemical_compoundQuality of lifeRetrospective Studieimmune system diseaseshemic and lymphatic diseasesInternal medicineRegorafenibmedicineHumansOriginal ResearchRetrospective StudiesGiSTbusiness.industryPhenylurea Compoundstoxicityhemic and immune systemspersonalized treatmentdigestive system diseasesquality of lifeOncologychemistryregorafenibGIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal TumorsbusinessHumanGISTESMO Open
researchProduct